Stratification of recurrence risk is a cornerstone of early breast cancer diagnosis that informs
a patient's optimal treatment pathway. Several tools exist that combine clinicopathological …

Breast cancer (BC) is the most common female cancer and the second cause of death
among women worldwide. The 5-year relative survival rate recently improved up to 90% due …

Background Axillary lymph node dissection (ALND) can be avoided in node-positive
patients who receive neoadjuvant chemotherapy (NAC) if three or more negative sentinel …

Neoadjuvant immunotherapy has emerged as a promising approach in the treatment of
various malignancies, with preclinical studies showing improved immune responses in the …

Introduction For patients with locally advanced estrogen receptor or progesterone receptor-
positive breast cancer, neoadjuvant endocrine therapy (NET) facilitates down-staging of the …

Immunotherapy is currently approved for a subset of patients diagnosed with advanced triple
negative breast cancer (TNBC), based on the phase III randomized controlled trial …

Background It is estimated that breast cancer (BC) incidence, especially that of early-stage
breast cancer cases continues to rise due to increased universal screening. Breast …

Objectives To investigate breast cancer-specific mortality by early breast cancer (EBC;
Stages I-IIIC) subtype; incidence of high-risk indicators for recurrence (defined in monarchE …

Abstract Purpose of Review To critically review the existing evidence on immune checkpoint
inhibitors (ICIs) in early-stage and metastatic breast cancer and discuss emerging strategies …

Triple-negative breast cancer (TNBC) accounts for 15% to 20% of all invasive breast
carcinomas and is defined by the lack of estrogen receptor, progesterone receptor, and …